Resolvyx Pharmaceuticals

... the end in inflammation

Board of Directors

The Resolvyx Board of Directors is comprised of:

Timothy J. Barberich - Chairman of the Board, Sepracor

Jean-Francois Formela, MD - Senior Partner, Atlas Venture

Doug Levinson, PhD - Partner, Flagship Ventures

Keith Manchester, M.D., Portfolio Manager, QVT Financial LP

George M. Milne, Jr., PhD - Venture Partner, Radius Ventures LLC

Paul Rubin, MD - President and Chief Executive Officer, Resolvyx Pharmaceuticals

Gregory Weinhoff, MD - Partner, CHL Medical Partners

The Resolvin "many-to-one" approach will, for the first time, address the immune system redundancy as a major obstacle to identifying highly efficacious therapies for chronic inflammatory diseases.